GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% premium over its 90-day volume-weighted average price and a 17% premium over its closing price on Feb.

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its neuromodulation platforms for treating chronic pain. | With Globus paying $5.85 for each of Nevro’s outstanding shares,